secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001558370-23-014281
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Q2 net loss narrows to $0.7M; DA-1241 Phase 2a dosing expected Sept 2023
--------------------------------------------------------------------------------

- Net loss of $0.7M ($0.02/share) in Q2 2023 vs $3.3M in Q2 2022; cash $28.7M sufficient into 2024.
- First patient dosing in Phase 2a trial of DA-1241 for NASH expected September 2023.
- Signed term sheet with MThera to out-license NB-01 for painful diabetic neuropathy worldwide except Korea.
- Preclinical data for DA-1726 shows superior weight loss vs semaglutide and tirzepatide; IND submission expected H2 2023.
- R&D expenses increased to $2.4M from $1.0M YoY, driven by DA-1241 preparation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/0001558370-23-014281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/nrbo-20230809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer